Whether a GLP-1 can replace mealtime insulin is a narrower question than whether it can replace other medicines. The insulin trials tested specific treatment plans for people with type 2 diabetes. Prescription records can only tell us what was recorded before and after people started a GLP-1 drug.
What changed in the prescription records?
Researchers studied 3,660 adults with type 2 diabetes who already had at least one other glucose-lowering drug recorded before starting a GLP-1 or tirzepatide. The number of other active substances recorded on or after initiation was lower for 17.2%, unchanged for 38.8%, and higher for 44.0% [1]. These records do not establish simultaneous use, dose changes or whether starting a GLP-1 caused anyone to add or stop another medication.
What did trials of mealtime insulin find?
A review of seven randomized trials included 1,332 adults with type 2 diabetes already using an intensive insulin regimen. Researchers tested strategies that reduced or withdrew scheduled mealtime insulin while keeping basal insulin. The HbA1c change differed by −0.08 percentage points versus continuing the prior regimen (95% CI −0.28 to 0.12). Total daily insulin use was lower on average [2]. Those trial averages cannot tell an individual how to change their insulin dose.
Which medications should a prescriber review?
The American Diabetes Association recommends that clinicians reassess drugs that can cause low blood sugar when adding a glucose-lowering medicine. Those drugs include insulin, sulfonylureas and meglitinides [3]. Bring an up-to-date medication list to that conversation so the clinician can consider why each drug was prescribed before changing it.